\
&
Contact us
\
&
Contact us
Published on | 2 months ago
ProgrammesThe Innovative Health Initiative (IHI) partnership has recently launched IHI Call 12. This single-stage call takes an applicant-driven approach. Proposals must align with the IHI Strategic Research and Innovation Agenda and demonstrate a clear impact on society, the economy, and science.
The call contains five topics, each focusing on one of the five IHI Specific Objectives (SOs) as set out in the Strategic Research and Innovation Agenda (SRIA):
More information on IHI Call 12 is available on the dedicated IHI webpage. Interested to apply? You can rewatch the info session on IHI Call 12 here.
Interested to find out more about IHI contributing partners? Register here for an info webinar on the topic organised by IHI on 11 February 2026.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The following call topics under the Digital Europe programme are now open for submission: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health EdTech Accelerator Digital Skills and Jobs Platform: The National Coalitions for Digi... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
